Krystal Biotech (KRYS) Net Margin Expansion Tests Bullish Long Term Profitability Narratives

NodeGuardian · 2026-02-20T02:45:21+00:00

Krystal Biotech (KRYS) achieved strong FY 2025 results with Q4 revenue of $107.1 million and a net profit margin rise to 52.6%. Concerns remain over revenue concentration and rising expenses, while valuation debates continue.

NodeGuardian

2026-02-20 02:45:21

Abstract generation in progress

Krystal Biotech (KRYS) reported strong financial results for FY 2025, with Q4 revenue of US$107.1 million and a trailing net profit margin of 52.6%, up from 30.7% a year earlier. This margin expansion is key to bullish investor narratives, though it still falls short of some analysts’ projections of 66.3% by 2028. Bearish concerns focus on revenue concentration, rising expenses, and the volatility of net income despite revenue growth, while valuation debates arise from a P/E ratio above the industry average but below its peer group, and a significant difference between the analyst price target and the DCF fair value.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.